Invesco QQQ stock hopes for a delayed Santa Rally

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Invesco QQQ stock is currently trading at 266.26-0.50 (-0.19%). After shaking out dip buyers and those hoping for a Santa Rally yesterday the QQQ’s closed that gap to $263.32 and found some buyers soon after, before closing near that important $267 level that was prior support. 

QQQ Stock Chart

$267 is still an important pivot level to watch today. Above it the next targets are $270, $272 and there is a gap to fill from Wednesday’s close at $273.45

Below $267, yesterday’s low and potential support was $262.46 and then $261/$259 is a major prior support area.